NCT05388890

Treatment of Atrophic Gastritis After HP Eradication With Modified Liujunzi Decoction Based on Syndrome Differentiation

Clinical Study on the Efficacy of Modified Liujunzi Prescription on the Treatment of Atrophic Gastritis After HP Eradication

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 286 (estimated)
• Sponsor: Peking University First Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is an observational cohort study of clinical efficacy study.The purpose of this topic is to evaluate the efficacy and safety of Modified Liujunzi Decoction based on syndrome differentiation in patients with chronic atrophic gastritis(CAG) after HP eradication.Taking Modified Liujunzi Decoction as the observation group and Weifuchun routine treatment as the control group, so as to provide evidence for the treatment of CAG and reduce the risk of gastric cancer. A total of 284 patients were included. The curative efficacy, symptom score and adverse events will be recorded and analyzed.

Conditions

• Chronic Atrophic Gastritis

Interventions

Type	Name	Description
DRUG	MLD	Modified Liujunzi Decoction is provided by the chinese pharmacy of Peking University First Hospital , one dose per day, taken in twice, and the course of treatment is 6 months.
DRUG	WFC	Chinese patent medicine, take according to the instructions, the course of treatment is 6 months.

Timeline

• Start date: 2022-08-02
• Primary completion: 2024-12-31
• Completion: 2025-12-31
• First posted: 2022-05-24
• Last updated: 2023-09-05

Locations

1 site across 1 country: China